VOLUME 2 (2011)
View Archive »
About The Cover
Accumulation of heat shock-induced GFP in aggresomes in bortezomib treated cells. The synthesis (HS36h), degradation (HS72h), and accumulation in aggresomes (HS/BZ72h) of GFP were monitored by fluorescent microscopy. See Workman et al. for commentary on Neznanov et al.
|
|
Table of Contents
|
| Mycoplasma and cancer: in search of the link |
|
https://doi.org/10.18632/oncotarget.264
|
| 271-273 |
|
| Pharmacological manipulation of the cell cycle and metabolism to protect normal tissues against conventional anticancer drugs |
|
https://doi.org/10.18632/oncotarget.265
|
| 274-276 |
|
| A stressful life or death: Combinatorial proteotoxic approaches to cancerselective therapeutic vulnerability |
|
https://doi.org/10.18632/oncotarget.266
|
| 277-280 |
|
| The “Infectious†Nature of Human Prostate Cancer: A Cautionary Note |
|
https://doi.org/10.18632/oncotarget.267
|
| 281-283 |
|
| Enhancing proteotoxic stress as an anticancer strategy |
|
https://doi.org/10.18632/oncotarget.268
|
| 284-286 |
|
| Detecting and monitoring lymphoma with highthroughput sequencing |
|
https://doi.org/10.18632/oncotarget.270
|
| 287-288 |
Research Papers
|
| Association of Mycoplasma hominis infection with prostate cancer |
|
https://doi.org/10.18632/oncotarget.256
|
| 289-297 |
|
| Thioaptamer Conjugated Liposomes for Tumor Vasculature Targeting |
|
https://doi.org/10.18632/oncotarget.261
|
| 298-304 |
Research Perspectives
|
| Caveolin1 in sarcomas: friend or foe |
|
https://doi.org/10.18632/oncotarget.255
|
| 305-312 |
|
| The beating heart of melanomas: a minor subset of cancer cells sustains tumor growth |
|
https://doi.org/10.18632/oncotarget.259
|
| 313-320 |
|
| INPP4B: the New Kid on the PI3K Block |
|
https://doi.org/10.18632/oncotarget.260
|
| 321-328 |
|
| Using quantitative proteomic analysis to understand genotype specific intrinsic drug resistance in melanoma |
|
https://doi.org/10.18632/oncotarget.263
|
| 329-335 |
|
| Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers |
|
https://doi.org/10.18632/oncotarget.262
|
| 336-346 |
|
| Mitochondrial Compartmentalized Protein Folding and Tumor Cell Survival |
|
https://doi.org/10.18632/oncotarget.273
|
| 347-351 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLCß
